title: Compared effectiveness of the 7-valent pneumococcal conjugate vaccine in children with the 13-valent vaccine in adults.
abstract: 13-valent-pneumococcal conjugated vaccine was recently approved in the USA and Europe for adults 50 years of age or more. But this approval was followed by recommendations limiting its use to immunocompromised and asplenic patients. The extension of indications to adults was based on the well-demonstrated clinical effectiveness in infants less than 2 years of age, and on a better immune response either quantitatively or qualitatively with conjugated vaccines compared to the immunogenicity of plain polysaccharide vaccines. Nevertheless, the issue was to know whether results observed with the 7-valent pneumococcal conjugate vaccine in children are reproducible in adults with the 13-valent. The answer was given by comparing the epidemiological and physiopathological data, and the immunological response of the two populations. Very few clinical effectiveness studies in adults are available. We had for aim to assess these various issues in infants and adults. A lot of questions remain, such as the unknown impact of serotype replacement with the 13-valent pneumococcal conjugated vaccine on the clinical epidemiology and emergent Streptococcus pneumoniae pathogenicity, while waiting for the CAPITA study results expected in 2014.
authors.affiliation: Service des maladies infectieuses, infectiologie, centre hospitalier de la région d'Annecy, 1, avenue de l'Hôpital-Metz-Tessy, BP 90074, 74374 Pringy cedex, France. jgaillat@ch-annecy.fr
authors.forename: J
authors.initials: J
authors.lastname: Gaillat
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000907:Antibodies, Bacterial / Q000096:biosynthesis* / Q000097:blood / Q000276:immunology; D002353:Carrier State / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D004306:Dose-Response Relationship, Immunologic; D005060:Europe / Q000453:epidemiology; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D032521:Immunity, Herd; D007117:Immunization, Secondary; D016867:Immunocompromised Host; D007223:Infant; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000503:physiopathology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000191:economics / Q000276:immunology*; D015203:Reproducibility of Results; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000145:classification / Q000276:immunology*; D014481:United States / Q000453:epidemiology; D014611:Vaccination; D018074:Vaccines, Conjugate / Q000191:economics / Q000276:immunology*
chemical_list: C538862:13-valent pneumococcal vaccine; D000907:Antibodies, Bacterial; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate
keywords: Adultes; Adults; Plain pneumococcal polysaccharide vaccine; Pneumococcal conjugate vaccine; Vaccin conjugué pneumococcique; Vaccin pneumococcique polysaccharidique